AMBUJACEM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | AMBUJACEM | Market Cap | 1,06,810 Cr. | Current Price | 430 ₹ | High / Low | 625 ₹ |
| Stock P/E | 27.3 | Book Value | 213 ₹ | Dividend Yield | 0.47 % | ROCE | 3.29 % |
| ROE | 7.70 % | Face Value | 2.00 ₹ | DMA 50 | 439 ₹ | DMA 200 | 492 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | -0.02 % | PAT Qtr | 1,742 Cr. | PAT Prev Qtr | -59.2 Cr. |
| RSI | 49.8 | MACD | -4.53 | Volume | 35,63,452 | Avg Vol 1Wk | 30,53,228 |
| Low price | 394 ₹ | High price | 625 ₹ | PEG Ratio | 2.01 | Debt to equity | 0.02 |
| 52w Index | 15.6 % | Qtr Profit Var | 214 % | EPS | 14.4 ₹ | Industry PE | 30.0 |
📊 Optimal Buy Price: 425–435 ₹ (near support zone)
💹 Profit-Taking Levels: 450–465 ₹ (short-term resistance)
🛑 Stop-Loss: 418 ₹
⏱️ Exit Strategy if Holding: Exit intraday if RSI falls below 48 or price slips under 425 ₹ with weakening momentum. Book profits if price moves into 450–465 ₹ zone with strong volume confirmation. Exit early if intraday volume drops below average and price fails to hold above 430 ₹.
✅ Positive
- Quarterly PAT recovery (₹1,742 Cr. vs -₹59.2 Cr.) shows strong turnaround
- EPS at ₹14.4 supports earnings visibility
- Debt-to-equity ratio of 0.02 indicates very low leverage
- FII holdings increased slightly (+0.03%)
- Volume (35.6 lakh) above weekly average (30.5 lakh) — strong participation
⚠️ Limitation
- ROCE (3.29%) and ROE (7.70%) are weak compared to peers
- Current price below both DMA 50 (439 ₹) and DMA 200 (492 ₹) — bearish trend
- MACD negative (-4.53) indicates bearish bias
- PEG ratio of 2.01 suggests expensive growth prospects
- 52-week index at 15.6% shows weak long-term performance
📉 Company Negative News
- No major external news reported, but DII holdings decreased (-0.02%)
📈 Company Positive News
- Quarterly profit variation of 214% highlights strong recovery
- Volume above weekly average indicates active participation
🏭 Industry
- Industry P/E at 30.0 shows sector is moderately valued
- AMBUJACEM trades slightly below industry average (P/E 27.3), reflecting cautious sentiment
🔎 Conclusion
AMBUJACEM shows fair but cautious intraday potential. Strong quarterly recovery and volume support are positives, but weak ROCE/ROE, negative MACD, and price below key moving averages limit conviction. Suitable for disciplined intraday buy near 425–435 ₹ with strict stop-loss at 418 ₹ and profit booking around 450–465 ₹.
For deeper insights, you could expand this into a swing trade setup, add sector overlays, or run a peer benchmarking to refine positioning.